This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://www.rxlist.com/cgi/generic3/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/kegg-compound/
n20http://linked.opendata.cz/resource/drugbank/company/
n29http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
n15http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/chemspider/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n6http://linked.opendata.cz/resource/drugbank/property/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00474/identifier/wikipedia/
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00474
rdf:type
n5:Drug
n5:description
An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]
n5:dosage
n16:271B5925-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
5.6 ± 2.7 minutes
n5:indication
Methohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
n5:manufacturer
n20:271B5923-363D-11E5-9242-09173F13E4C5
owl:sameAs
n8:DB00474 n27:DB00474
dcterms:title
Methohexital
adms:identifier
n4:46507954 n9:C07844 n10:8683 n11:DB00474 n12:9034 n13:D04985 n15:42023-105-01 n21:PA164784030 n22:Methohexital n25:102216
n5:mechanismOfAction
Methohexital binds at a distinct binding site associated with a Cl<sup>-</sup> ionopore at the GABA<sub>A</sub> receptor, increasing the duration of time for which the Cl<sup>-</sup> ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
n5:packager
n20:271B5921-363D-11E5-9242-09173F13E4C5 n20:271B5922-363D-11E5-9242-09173F13E4C5
n5:routeOfElimination
Excretion occurs via the kidneys through glomerular filtration.
n5:synonym
Metohexital Methohexital Methohexitalum 5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione (+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid 5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid 5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione Methohexitone alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
n5:toxicity
The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
n5:proteinBinding
73%
n5:salt
n28:hasConcept
n29:M0013589
foaf:page
n18:methohexital.html n19:methohexital.htm
n5:IUPAC-Name
n6:271B592A-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5930-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B592F-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B592C-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B592D-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B592E-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5928-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5929-363D-11E5-9242-09173F13E4C5 n6:271B5926-363D-11E5-9242-09173F13E4C5 n6:271B593F-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5927-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:N05CA15 n24:N01AF01
n5:H-Bond-Acceptor-Count
n6:271B5936-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5937-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5931-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5932-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5934-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5933-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5935-363D-11E5-9242-09173F13E4C5
n5:absorption
The absolute bioavailability following rectal administration of methohexital is 17%.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
151-83-7
n5:category
n5:containedIn
n26:271B5924-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n6:271B593B-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B593D-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B593E-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B593A-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5939-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B593C-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B592B-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5938-363D-11E5-9242-09173F13E4C5